Search Results
An Overview of a Phase II Study of ONT-380 in HER2-Positive Breast Cancer
ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast Cancer
Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer
Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer
Dr. Erika P. Hamilton on ONT-380 in HER2-Positive Breast Cancer Patients With Brain Metastases
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Dr. Kirkman on the Development of the HER2-Specific Inhibitor ONT-380 for Breast Cancer
Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer
Dr. Hamilton on Phase 1 Trial for HER2 Positive Breast Cancer - Sarah Cannon
Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer
Phase I/II study of a novel SERCA in ER+ HER2- BC
Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer
